News

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

Inhaled teicoplanin completed phase 1 clinical trial in cystic fibrosis

18 marzo 2021
Neupharma announces the positive conclusion of the phase 1 study, conducted at the “Azienda Ospedaliera Universitaria Integrata” of Verona, with the formulation of inhaled teicoplanin in CF patients.
Neupharma is included among the 400 companies deserving the

Neupharma is included among the 400 companies deserving the "CHAMPION OF GROWTH" Certification 2016/2019

12 ottobre 2020
The German Quality and Finance Institute published the results of the research entitled "Champions of Growth": the aim was rewarding the 400 companies whose turnover increased most in the three-year period 2016-2019.
The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

The Food and Drug Administration granted Teicoplanin the PEDIATRIC Orphan Drug Designation

28 settembre 2020
The Food and Drug Administration has granted the Pediatric Orphan Drug Designation to the inhaled formulation of Teicoplanin for patients with Cystic Fibrosis.
Neupharma wins the title

Neupharma wins the title

03 giugno 2020
Neupharma, one of the finalists for the category "Companies - Health & Pharma" from “Le Fonti Awards”, wins the title "Excellence of the Year - Innovation & Leadership - Medical Devices for Cystic Fibrosis"
NEUPHARMA and PARI are launching the DM PARI Service

NEUPHARMA and PARI are launching the DM PARI Service

01 giugno 2020
The new area of the website “DM PARI Service” is online and ready to be consulted
NEUPHARMA NEW WEBSITE

NEUPHARMA NEW WEBSITE

07 maggio 2020
May 7, 2020: NEUPHARMA 2020 SITE IS ONLINE
Neupharma donated FFP2 Masks to Red Cross

Neupharma donated FFP2 Masks to Red Cross

05 maggio 2020
Imola, 4 May 2020: Imola Red Cross continues a constant activity to face COVID-19 emergency thanks to the community aids.

The new Neupharma headquarters

02 settembre 2019
Imola, 02 September 2019: Neupharma inaugurates the new corporate headquarters in the city centre of Imola.
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula

The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula

23 agosto 2017
The European Commission has granted the designation of orphan drug to Teicoplanin in inhalation formula for cystic fibrosis, a formula developed by Neupharma in collaboration with the non-profit company Rare Partners.